AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 25. Analyst Terence Flynn from Morgan Stanley reiterated a Buy rating on the stock and has a $250.00 price target.
Terence Flynn’s rating is based on AbbVie’s strong financial performance and promising growth prospects. The company reported better-than-expected first-quarter results and increased its revenue and earnings guidance for 2025, driven by the continued success of its key immunology products, Skyrizi and Rinvoq. These products have shown robust sales growth, outperforming market expectations, which supports the company’s long-term growth trajectory.
Moreover, despite some softness in the aesthetics segment and potential impacts from tariffs, AbbVie is actively working on mitigation strategies, including leveraging its extensive manufacturing footprint in the U.S. and implementing cost efficiencies. The stock’s current valuation, trading at a price-to-earnings ratio of approximately 15x for 2025 and 12x for 2026, presents an attractive opportunity for investors, aligning with Flynn’s positive outlook on the company’s future performance.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABBV in relation to earlier this year.